专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL282968D0 Anti-nkg2a antibodies and uses thereof 未知
公开(公告)号：IL282968D0
公开(公告)日：2021-06-30
申请号：IL28296821
申请日：2021-05-05
申请人： SQUIBB BRISTOL MYERS CO , BEZMAN NATALIE A , KORMAN ALAN J , DESHPANDE SHRIKANT , JHATAKIA AMY D , HUANG RICHARD Y , CHEN GUODONG , RAKESTRAW GINGER C , HENNING KARLA ANN , RANGAN VANGIPURAM S , BEE CHRISTINE , SHAO XIANG
发明人： BEZMAN NATALIE A , KORMAN ALAN J , DESHPANDE SHRIKANT , JHATAKIA AMY D , HUANG RICHARD Y , CHEN GUODONG , RAKESTRAW GINGER C , HENNING KARLA ANN , RANGAN VANGIPURAM S , BEE CHRISTINE , SHAO XIANG
IPC分类号： A61K39/00 , A61K39/395 , A61K47/68 , A61P35/00 , C07K16/28 , G01N33/68
摘要： The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

2. 发明专利

IL265625D0 Activatable anti-ctla-4 antibodies and uses thereof 未知
公开(公告)号：IL265625D0
公开(公告)日：2019-05-30
申请号：IL26562519
申请日：2019-03-26
申请人： SQUIBB BRISTOL MYERS CO , CYTOMX THERAPEUTICS INC , TIPTON KIMBERLY ANN , WEST JAMES WILLIAM , DESHPANDE SHRIKANT , ENGELHARDT JOHN J
发明人： TIPTON KIMBERLY ANN , WEST JAMES WILLIAM , DESHPANDE SHRIKANT , ENGELHARDT JOHN J
IPC分类号： C07K20060101
摘要： Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated with anti-CTLA-4 activity outside the tumor.

3. 发明申请

WO9957241A9 MYELIN BASIC PROTEIN PEPTIDES AND USES THEREOF 审中-公开
标题翻译： MYELIN基本蛋白肽及其用途
公开(公告)号：WO9957241A9
公开(公告)日：2000-02-17
申请号：PCT/US9909930
申请日：1999-05-05
申请人： CORIXA CORP , ARIMILLI SUBHASHINI , DESHPANDE SHRIKANT
发明人： ARIMILLI SUBHASHINI , DESHPANDE SHRIKANT
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61P25/00 , A61P43/00 , C07K14/47 , C07K16/18 , C07K16/28 , C07K16/40 , C07K19/00 , C12N5/10 , C12N15/12 , C12Q1/02 , C12N5/08 , A61K38/17 , C12N15/62 , C12N15/85
CPC分类号： C07K14/4713 , A61K38/00
摘要： This invention pertains generally to the treatment of autoimmune diseases of the central nervous system characterized by demyelination. In particular, this invention pertains to novel peptides derived from human myelin basic protein (MBP). When complexed with the appropriate major histocompatibility complex (MHC) molecule, these peptides can be used to treat multiple sclerosis and other demyelinating autoimmune diseases.
摘要翻译：本发明一般涉及治疗以脱髓鞘为特征的中枢神经系统的自身免疫性疾病。具体而言，本发明涉及源自人髓磷脂碱性蛋白（MBP）的新型肽。当与合适的主要组织相容性复合物（MHC）分子复合时，这些肽可用于治疗多发性硬化和其他脱髓鞘自身免疫性疾病。

4. 发明申请

WO2004079534A2 SYSTEM AND METHOD FOR DYNAMIC RESOURCE RECONFIGURATION USING A DEPENDENCY GRAPH 审中-公开
标题翻译：使用附图进行动态资源重构的系统和方法
公开(公告)号：WO2004079534A2
公开(公告)日：2004-09-16
申请号：PCT/US2004/006452
申请日：2004-03-03
申请人： SUN MICROSYSTEMS, INC. , MURPHY, Richard, C. , CARTER, Scott, M. , ORNELAS, Mario, G. , DESHPANDE, Shrikant
发明人： MURPHY, Richard, C. , CARTER, Scott, M. , ORNELAS, Mario, G. , DESHPANDE, Shrikant
IPC分类号： G06F
CPC分类号： G06F9/5077
摘要： A system and method for predicting whether a dynamic reconfiguration of a resource of a resource domain would be successful, prior to attempting the reconfiguration. A resource domain includes one or more computer resources (e.g., physical, logical and pseudo devices) and a graph management agent configured to maintain a graph representing the resources and dependencies between resources. Vertices of the graph represent resources; edges represent dependencies. A resource domain may also include a set of policies or constraints regarding resources and reconfigurations of resources. An illustrative constraint may specify that a multi-pathed logical device must have a minimal number of paths (e.g., two). The graph agent identifies the effect the dynamic reconfiguration operation would have upon the resources and dependencies, and determines whether any constraints would be violated. If no constraints would be violated, the graph management agent may indicate that the reconfiguration would succeed.
摘要翻译：在尝试重新配置之前，用于预测资源域的资源的动态重新配置是否将成功的系统和方法。资源域包括一个或多个计算机资源（例如，物理，逻辑和伪设备）以及图形管理代理，其被配置为维护表示资源的资源和资源之间的依赖关系。图的顶点代表资源; 边缘表示依赖关系。资源域还可以包括关于资源的资源和重新配置的一组策略或约束。说明性的约束可以指定多播路逻辑设备必须具有最小数量的路径（例如，两个）。图形代理识别动态重新配置操作对资源和依赖关系的影响，并确定是否违反任何约束。如果不违反任何限制，则图形管理代理可以指示重新配置将成功。

5. 发明申请

WO03029279A9 IMMUNODOMINANT ACETYLCHOLINE RECEPTOR ALPHA SUBUNIT PEPTIDE: MHC COMPLEXES 审中-公开
标题翻译：免疫抑制剂乙酰胆碱受体ALPHA亚基肽：MHC复合物
公开(公告)号：WO03029279A9
公开(公告)日：2004-04-22
申请号：PCT/US0231621
申请日：2002-10-02
申请人： CORIXA CORP , SPACK EDWARD , ARMILLI SUBHASHINI , DESHPANDE SHRIKANT , WEHNER NANCY
发明人： SPACK EDWARD , ARMILLI SUBHASHINI , DESHPANDE SHRIKANT , WEHNER NANCY
IPC分类号： A61K38/00 , C07K14/705 , C07K14/74 , A61K39/385 , A61K38/16 , C07K1/00
CPC分类号： C07K14/70571 , A61K38/00 , C07K14/70539 , C07K2319/00
摘要： The present invention is directed to the treatment of autoimmune diseases, in particular of myasthenia gravis. This invention provides novel autoimmune dominant peptides derived from the acetylcholine receptor, as well as methods for preparing the peptides. The present invention further provides complexes comprising these peptides associated with an appropriate major histocompatibility complex (MHC) molecule and methods for making these complexes. The complexes of the present invention can be used therapeutically or prophylactically for treating myasthenia gravis.
摘要翻译：本发明涉及治疗自身免疫性疾病，特别是重症肌无力。本发明提供了源自乙酰胆碱受体的新型自身免疫优势肽以及制备肽的方法。本发明还提供了包含与适合的主要组织相容性复合物（MHC）分子相关联的这些肽的复合物和制备这些复合物的方法。本发明的复合物可以治疗或预防用于治疗重症肌无力。

6. 发明申请

WO2005058815A2 IP-10 ANTIBODIES AND THEIR USES 审中-公开
标题翻译： IP-10抗体及其用途
公开(公告)号：WO2005058815A2
公开(公告)日：2005-06-30
申请号：PCT/US2004/041506
申请日：2004-12-10
申请人： MEDAREX, INC. , DESHPANDE, Shrikant , HUANG, Haichun , SRINIVASAN, Mohan , CARDARELLI, Josephine, M. , WANG, Changyu , PASSMORE, David , RANGAN, Vangipuram, S. , LANE, Thomas, E. , KEIRSTEAD, Hans, S. , LIU, Michael, T.
发明人： DESHPANDE, Shrikant , HUANG, Haichun , SRINIVASAN, Mohan , CARDARELLI, Josephine, M. , WANG, Changyu , PASSMORE, David , RANGAN, Vangipuram, S. , LANE, Thomas, E. , KEIRSTEAD, Hans, S. , LIU, Michael, T.
IPC分类号： C07D
CPC分类号： C07K16/24 , A61K2039/505 , C07K14/522 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP- 10 with high affinity, inhibit the binding of IP- 10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
摘要翻译：本发明提供以高亲和力结合IP-10的分离的单克隆抗体，特别是人抗体，抑制IP-10与其受体的结合，抑制IP-10诱导的钙通量并抑制IP-10诱导的细胞迁移。还提供了编码本发明抗体的核酸分子，表达载体，宿主细胞和用于表达本发明的抗体的方法。还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。本发明还提供了使用本发明的抗体来抑制IP-10活性的方法，包括治疗各种炎性和自身免疫性疾病的方法。

7. 发明申请

WO2003029279A3 IMMUNODOMINANT ACETYLCHOLINE RECEPTOR ALPHA SUBUNIT PEPTIDE: MHC COMPLEXES 审中-公开
公开(公告)号：WO2003029279A3
公开(公告)日：2003-04-10
申请号：PCT/US2002/031621
申请日：2002-10-02
申请人： CORIXA CORPORATION , SPACK, Edward , ARMILLI, Subhashini , DESHPANDE, Shrikant , WEHNER, Nancy
发明人： SPACK, Edward , ARMILLI, Subhashini , DESHPANDE, Shrikant , WEHNER, Nancy
IPC分类号： A61K39/385
摘要： The present invention is directed to the treatment of autoimmune diseases, in particular of myasthenia gravis. This invention provides novel autoimmune dominant peptides derived from the acetylcholine receptor, as well as methods for preparing the peptides. The present invention further provides complexes comprising these peptides associated with an appropriate major histocompatibility complex (MHC) molecule and methods for making these complexes. The complexes of the present invention can be used therapeutically or prophylactically for treating myasthenia gravis.

8. 发明申请

WO1991018012A1 CELL INTERNALIZABLE CONJUGATES AND COMPLEXES INCLUDING INTRACELLULARLY CLEAVABLE MOIETIES 审中-公开
标题翻译：细胞内含子和复合物，包括细胞内可溶性动物
公开(公告)号：WO1991018012A1
公开(公告)日：1991-11-28
申请号：PCT/US1991003352
申请日：1991-05-14
申请人： BIOSPAN CORPORATION , CLARK, Brian, R. , DESHPANDE, Shrikant , NAG, Bishwajit
发明人： BIOSPAN CORPORATION
IPC分类号： C07K07/00
CPC分类号： C07K17/06 , A61K9/1271 , A61K38/00 , A61K47/543 , A61K47/6425 , Y10T428/2984
摘要： Cell internalizable and intracellularly cleavable conjugates and complexes of therapeutically or diagnostically effective moieties are described. A novel system for delivery of such moieties is provided.
摘要翻译：描述了细胞内化和细胞内可裂解的缀合物和治疗或诊断有效部分的复合物。提供了一种用于递送这种部分的新系统。

9. 发明申请

WO2005058815A3 IP-10 ANTIBODIES AND THEIR USES 审中-公开
标题翻译： IP-10抗体及其用途
公开(公告)号：WO2005058815A3
公开(公告)日：2006-02-23
申请号：PCT/US2004041506
申请日：2004-12-10
申请人： MEDAREX INC , DESHPANDE SHRIKANT , HUANG HAICHUN , SRINIVASAN MOHAN , CARDARELLI JOSEPHINE M , WANG CHANGYU , PASSMORE DAVID , RANGAN VANGIPURAM S , LANE THOMAS E , KEIRSTEAD HANS S , LIU MICHAEL T
发明人： DESHPANDE SHRIKANT , HUANG HAICHUN , SRINIVASAN MOHAN , CARDARELLI JOSEPHINE M , WANG CHANGYU , PASSMORE DAVID , RANGAN VANGIPURAM S , LANE THOMAS E , KEIRSTEAD HANS S , LIU MICHAEL T
IPC分类号： A61K39/395 , C07D20060101 , C07K14/52 , C07K16/24 , C07K16/28 , C07H21/04 , C12N5/10 , C12N15/00 , C12N15/63
CPC分类号： C07K16/24 , A61K2039/505 , C07K14/522 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP- 10 with high affinity, inhibit the binding of IP- 10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
摘要翻译：本发明提供以高亲和力结合IP-10的分离的单克隆抗体，特别是人抗体，抑制IP-10与其受体的结合，抑制IP-10诱导的钙通量并抑制IP-10诱导的细胞迁移。还提供了编码本发明抗体的核酸分子，表达载体，宿主细胞和用于表达本发明的抗体的方法。还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。本发明还提供了使用本发明的抗体来抑制IP-10活性的方法，包括治疗各种炎性和自身免疫性疾病的方法。

10. 发明申请

WO2004079534A3 SYSTEM AND METHOD FOR DYNAMIC RESOURCE RECONFIGURATION USING A DEPENDENCY GRAPH 审中-公开
标题翻译：使用附图进行动态资源重构的系统和方法
公开(公告)号：WO2004079534A3
公开(公告)日：2005-12-22
申请号：PCT/US2004006452
申请日：2004-03-03
申请人： SUN MICROSYSTEMS INC , MURPHY RICHARD C , CARTER SCOTT M , ORNELAS MARIO G , DESHPANDE SHRIKANT
发明人： MURPHY RICHARD C , CARTER SCOTT M , ORNELAS MARIO G , DESHPANDE SHRIKANT
IPC分类号： G06F9/50
CPC分类号： G06F9/5077
摘要： A system and method for predicting whether a dynamic reconfiguration of a resource of a resource domain would be successful, prior to attempting the reconfiguration. A resource domain includes one or more computer resources (e.g., physical, logical and pseudo devices) and a graph management agent configured to maintain a graph representing the resources and dependencies between resources. Vertices of the graph represent resources; edges represent dependencies. A resource domain may also include a set of policies or constraints regarding resources and reconfigurations of resources. An illustrative constraint may specify that a multi-pathed logical device must have a minimal number of paths (e.g., two). The graph agent identifies the effect the dynamic reconfiguration operation would have upon the resources and dependencies, and determines whether any constraints would be violated. If no constraints would be violated, the graph management agent may indicate that the reconfiguration would succeed.
摘要翻译：在尝试重新配置之前，用于预测资源域的资源的动态重新配置是否将成功的系统和方法。资源域包括一个或多个计算机资源（例如，物理，逻辑和伪设备）以及图形管理代理，其被配置为维护表示资源的图表和资源之间的依赖关系。图的顶点代表资源; 边缘表示依赖关系。资源域还可以包括关于资源的资源和重新配置的一组策略或约束。说明性的约束可以指定多播路逻辑设备必须具有最小数量的路径（例如，两个）。图形代理识别动态重新配置操作对资源和依赖关系的影响，并确定是否违反任何约束。如果不违反任何限制，则图形管理代理可以指示重新配置将成功。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式